Keywords: AstraZeneca, Brilinta, FDA advisory, Acute coronary syndromes, Second-quarter 2010 financial results
US FDA advisory panel backs AstraZeneca’s Brilinta, as firm posts 22% rise in core EPS for 2nd-qtr 2010
Article | 29 July 2010
The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee has recommended the approval of Anglo-Swedish drug major AstraZeneca’s investigational drug ticagrelor - provisional trade name Brilinta - for the reduction of thrombotic events in patients with acute coronary syndromes (ACS, or blocked arteries), the company revealed last night.
M Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer returns worldwide rights to Celldex Thera’s rindopepimut brain tumor vaccine candidate
- India’s Natco challenges Celgene’s Revlimid patent in USA; new CFO named
- Roche plans job cuts, announcing Operational Excellence initiative
- US FDA makes label change on Pfizer’s Tygacil to reflect increased mortality risk
- Weighted average drug price cuts of 20% for over 4,000 drugs enforced in Greece as of today
